Syndax Pharmaceuticals Inc.
400 Totten Pond Road
Suite 110
Waltham
Massachusetts
02451
United States
Tel: 781-419-1400
Fax: 781-419-1420
Website: http://www.syndax.com/
Email: info@syndax.com
208 articles with Syndax Pharmaceuticals Inc.
-
Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day
5/11/2022
Syndax Pharmaceuticals, Inc. announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a panel discussion on targeted oncology at Citi's Biopharma Virtual Co-Panel Day on Wednesday, May 18, 2022 at 1:30 p.m. ET.
-
Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update
5/9/2022
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended March 31, 2022.
-
Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022
5/2/2022
Syndax Pharmaceuticals, Inc. today announced that it will release its first quarter 2022 financial results on Monday, May 9, after the close of the U.S. financial markets.
-
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Mar 04, 2022
3/4/2022
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that in connection with the hiring, announced on March 1, 2022, of Catherine Madigan, M.D., as Chief Medical Officer, Dr. Madigan received an inducement award to purchase up to 180,000 shares of common stock.
-
Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update
3/1/2022
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2021. In addition, the Company provided a clinical and business update.
-
Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer
3/1/2022
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Kate Madigan, M.D., to the role of Chief Medical Officer, effective immediately.
-
Syndax Announces Participation at Two Upcoming Investor Conferences - Feb 28, 2022
2/28/2022
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that members of its management team will participate in two upcoming investor conferences.
-
Syndax to Announce Fourth Quarter and Year-end 2021 Financial Results and Host Conference Call and Webcast on March 1, 2022
2/22/2022
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will release its fourth quarter and year-end 2021 financial results on Tuesday, March 1, after the close of the U.S. financial markets.
-
StrideBio, Exicure and Syndax Pharmaceuticals tapped new CEOs.
-
Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development
2/3/2022
Syndax Pharmaceuticals, Inc. today announced that Michael A. Metzger , President and Chief Operating Officer, will transition to the role of Chief Executive Officer, effective today.
-
Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference
1/20/2022
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at B. Riley Securities' 2022 Oncology Conference.
-
Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference
1/7/2022
Syndax Pharmaceuticals, Inc. today announced that Briggs W. Morrison , M.D., Chief Executive Officer of Syndax, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 08:15 a.m. ET.
-
Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia
12/22/2021
Syndax Pharmaceuticals, Inc. today announced that the European Commission has granted Orphan Drug Designation to SNDX-5613.
-
Syndax Announces Pricing of $75.3 Million Public Offering
12/16/2021
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced the pricing of an underwritten public offering of 3,157,144 shares of its common stock, and to certain investors pre-funded warrants to purchase 1,142,856 shares of its common stock at an exercise price of $0.0001.
-
Syndax Announces Proposed Public Offering of Common Stock - Dec 15, 2021
12/15/2021
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
-
Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613
12/13/2021
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), today announced updated positive data from the Phase 1 dose escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed lineage leukemia rearranged (MLLr) relapsed/refractory (R/R) acute leukemias.
-
The following features are highlights from the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, held in-person in Atlanta, GA, and virtually from December 11 to 14.
-
Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease
12/11/2021
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced updated positive data from its Phase 1/2 trial of axatilimab in patients with recurrent or refractory chronic graft-versus-host disease despite two or more prior lines of therapy.
-
Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update
11/15/2021
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter ended September 30, 2021. In addition, the Company provided a clinical and business update.
-
Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021
11/8/2021
Syndax Pharmaceuticals, Inc. announced today that it will release its third quarter 2021 financial results on Monday, November 15, after the close of the U.S. financial markets.